AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33151286 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus taxane (paclitaxel 80 mg/m2 weekly or docetaxel 75 mg/m2 every 3 weeks)
Number of subjects: 164
Study 33151286 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoximod plus taxane
Number of subjects: 164
Study 33151286 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus taxane
Number of subjects: 164
Study 32925066 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpinal direct current stimulation (tsDCS) at 2 mA for 20 minutes over thoracic vertebrae (IX-X) combined with cognitive training.
Number of subjects: 16
Study 32925066 — intervention group
Group type: COMPARATOR
Intervention: Sham condition (placebo stimulation) combined with cognitive training.
Number of subjects: 16
Study 35574743 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pressure extubation
Number of subjects: 105
Study 35574743 — intervention group
Group type: COMPARATOR
Intervention: Negative pressure extubation
Number of subjects: 105
Study 35574743 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 105
Study 33444206 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised dietary advice and protein-enriched food products to increase protein intake to at least 1.2 g/kg adjusted BW/day
Number of subjects: 264
Study 33444206 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised dietary advice and protein-enriched food products plus advice to consume 7.5-10 g protein through protein-enriched foods within half an hour after usual physical activity
Number of subjects: 264
Study 33444206 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 264
Study 33444206 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised dietary advice and protein-enriched food products
Number of subjects: 264
Study 33444206 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 264
Study 36412160 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexidol and Mexidol FORTE 250
Number of subjects: 318
Study 36412160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 32065000 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 97
Study 32065000 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor
Number of subjects: 97
Study 33309849 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel‐releasing intrauterine system (LNG‐IUS)
Number of subjects: 276
Study 33309849 — intervention group
Group type: COMPARATOR
Intervention: Endometrial ablation
Number of subjects: 276
Study 33309849 — intervention group
Group type: COMPARATOR
Intervention: Observational cohort
Number of subjects: 276
Study 33309849 — intervention group
Group type: COMPARATOR
Intervention: Randomised controlled trial (RCT)
Number of subjects: 276
Study 33354268 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home local vibration therapy (LVT) with NOVAFON Pro Sk2/2: 50/100 Hz, applied bilaterally for 16 minutes daily for 1 week
Number of subjects: 54
Study 33354268 — intervention group
Group type: COMPARATOR
Intervention: Inactive devices (placebo)
Number of subjects: 54
Study 35400584 — intervention group
Group type: EXPERIMENTAL
Intervention: Emibetuzumab plus Erlotinib (750 mg every 2 weeks + 150 mg once daily)
Number of subjects: 111
Study 35400584 — intervention group
Group type: EXPERIMENTAL
Intervention: Emibetuzumab monotherapy (750 mg every 2 weeks)
Number of subjects: 111
Study 35400584 — intervention group
Group type: EXPERIMENTAL
Intervention: Emibetuzumab plus Erlotinib
Number of subjects: 111
Study 35400584 — intervention group
Group type: EXPERIMENTAL
Intervention: Emibetuzumab monotherapy
Number of subjects: 111
Study 34611219 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord serum concentrations of perfluorooctane sulfonate (PFOS)
Number of subjects: 600
Study 34611219 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord serum concentrations of perfluorooctanoic acid (PFOA)
Number of subjects: 600
Study 34825590 — intervention group
Group type: EXPERIMENTAL
Intervention: Buddy-style intervention (5-10 min weekly)
Number of subjects: 65
Study 34825590 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard home exercise program)
Number of subjects: 65
Study 33260423 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (aerobic and resistance training 3-4 days/week at 60% HRres for aerobic and 50% RM for resistance)
Number of subjects: 139
Study 33260423 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity exercise (same training but at 80% HRres for half of the aerobic training, and 70% RM for resistance)
Number of subjects: 139
Study 33260423 — intervention group
Group type: COMPARATOR
Intervention: Control (usual lifestyle)
Number of subjects: 139
Study 33205676 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy goals
Number of subjects: 21
Study 33205676 — intervention group
Group type: COMPARATOR
Intervention: Difficult goals
Number of subjects: 21
Study 33653760 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health literacy intervention using smartphone and internet, focusing on hygiene and prevention, and coronavirus awareness and prevention for 3 months
Number of subjects: 1000
Study 33653760 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1000
Study 32620359 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS program (8-week intervention consisting of 6 individual in-home sessions, 3 group support sessions, and 2 telephone sessions)
Number of subjects: 969
Study 32620359 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS program
Number of subjects: 969
Study 32620359 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 969
Study 35343620 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-exposure tacrolimus (LE)
Number of subjects: 62
Study 35343620 — intervention group
Group type: COMPARATOR
Intervention: Standard-exposure tacrolimus (SE)
Number of subjects: 62
Study 35343620 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LE and SE)
Number of subjects: 62
Study 34364679 — intervention group
Group type: EXPERIMENTAL
Intervention: Human coding (N = 101)
Number of subjects: 343
Study 34364679 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer coding (N = 242)
Number of subjects: 343
Study 34364679 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis
Number of subjects: 343
Study 32335159 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient blend supplementation for 6 weeks
Number of subjects: 63
Study 32335159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 34269933 — intervention group
Group type: COMPARATOR
Intervention: Control (Group 1)
Number of subjects: 80
Study 34269933 — intervention group
Group type: EXPERIMENTAL
Intervention: T-Pro (Group 2)
Number of subjects: 80
Study 34269933 — intervention group
Group type: EXPERIMENTAL
Intervention: HyFlex CM (Group 3)
Number of subjects: 80
Study 34269933 — intervention group
Group type: EXPERIMENTAL
Intervention: ZenFlex (Group 4)
Number of subjects: 80
Study 34269933 — intervention group
Group type: EXPERIMENTAL
Intervention: TG6 (Group 5)
Number of subjects: 80
Study 32803473 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-5L health-related quality of life questionnaire
Number of subjects: 87
Study 32803473 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-5L
Number of subjects: 87
Study 32803473 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D index
Number of subjects: 87
Study 32803473 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-VAS
Number of subjects: 87
Study 35738778 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ivermectin (12 mg)
Number of subjects: 393
Study 35738778 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose ivermectin (24 mg)
Number of subjects: 393
Study 33212069 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence to guidelines for incidental nodules
Number of subjects: 514
Study 33212069 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence to guidelines for screening-detected nodules
Number of subjects: 514
Study 33212069 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief that benefits of adherence outweigh harms for incidental nodules
Number of subjects: 514
Study 33212069 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief that benefits of adherence outweigh harms for screening-detected nodules
Number of subjects: 514
Study 33212069 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of high-quality evidence for screening-detected nodules
Number of subjects: 514
Study 33212069 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of high-quality evidence for incidental nodules
Number of subjects: 514
Study 33212069 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief that frequency of recommended follow-up is 'just right' for both guidelines
Number of subjects: 514
Study 33212069 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief in high-quality evidence among nonintegrated health care system radiologists
Number of subjects: 514
Study 33212069 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief in high-quality evidence among integrated health care system radiologists
Number of subjects: 514
Study 33212069 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief that benefits of adherence outweigh harms among nonintegrated health care system radiologists
Number of subjects: 514
Study 33212069 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief that benefits of adherence outweigh harms among integrated health care system radiologists
Number of subjects: 514
Study 33212069 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness and self-reported adherence among low-volume readers
Number of subjects: 514
Study 36270309 — intervention group
Group type: EXPERIMENTAL
Intervention: HFO-guided tailoring
Number of subjects: 78
Study 36270309 — intervention group
Group type: COMPARATOR
Intervention: Spike-guided tailoring
Number of subjects: 78
Study 36270309 — intervention group
Group type: EXPERIMENTAL
Intervention: HFO-guided tailoring (for temporal lobe epilepsy)
Number of subjects: 78
Study 36270309 — intervention group
Group type: EXPERIMENTAL
Intervention: HFO-guided tailoring (for extratemporal lobe epilepsy)
Number of subjects: 78
Study 36270309 — intervention group
Group type: EXPERIMENTAL
Intervention: HFO-guided tailoring (adjusted for confounders)
Number of subjects: 78
Study 36270309 — intervention group
Group type: EXPERIMENTAL
Intervention: HFO-guided tailoring (for temporal lobe epilepsy, adjusted)
Number of subjects: 78
Study 36270309 — intervention group
Group type: EXPERIMENTAL
Intervention: HFO-guided tailoring (for extratemporal lobe epilepsy, adjusted)
Number of subjects: 78
Study 36270309 — intervention group
Group type: EXPERIMENTAL
Intervention: HFO-guided tailoring and Spike-guided tailoring
Number of subjects: 78
Study 33321192 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT-SIB
Number of subjects: 502
Study 33321192 — intervention group
Group type: COMPARATOR
Intervention: 3-D-CRT-seqB
Number of subjects: 502
Study 32016466 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine mesylate (DFO) for 48 hours
Number of subjects: 0
Study 32016466 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 0
Study 34250609 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 221
Study 32052907 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of combination formulation of vitamin C, vitamin E, and ferulic acid after Q-switched Nd:YAG laser treatment
Number of subjects: 18
Study 32052907 — intervention group
Group type: COMPARATOR
Intervention: Untreated side of the face (Control)
Number of subjects: 18
Study 35791276 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) upgrade
Number of subjects: 360
Study 35791276 — intervention group
Group type: COMPARATOR
Intervention: Conventional pacemaker (PM) devices
Number of subjects: 360
Study 33639484 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic stimulation (STIM) delivered on the up-phase of the slow wave and at constant 1-s inter-tone-intervals once N3 was identified
Number of subjects: 25
Study 33639484 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (SHAM) at inaudible decibels during equivalent stimulation periods
Number of subjects: 25
Study 32741099 — intervention group
Group type: EXPERIMENTAL
Intervention: Retzius-sparing robot-assisted radical prostatectomy (posterior approach)
Number of subjects: 110
Study 32741099 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach (anterior approach)
Number of subjects: 110
Study 34610611 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifunctional cocktail injected into the incision before wound closure
Number of subjects: 90
Study 34610611 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injected and patient‐controlled analgesic pump used (Control)
Number of subjects: 90
Study 34610611 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 90
Study 32240186 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentoring program with monthly one-on-one and group sessions
Number of subjects: 273
Study 32240186 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 273
Study 34427475 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy with the detachable Solitaire thrombectomy device and best medical therapy (BMT)
Number of subjects: 318
Study 34427475 — intervention group
Group type: COMPARATOR
Intervention: Best medical therapy (BMT) alone
Number of subjects: 318
Study 34427475 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy with the detachable Solitaire thrombectomy device
Number of subjects: 318
Study 33227335 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB)
Number of subjects: 230
Study 33227335 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stent (DES)
Number of subjects: 230
Study 35614161 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronomic chemotherapy (OMC) with celecoxib 200 mg twice daily and methotrexate 15 mg/m2 weekly for 12 months
Number of subjects: 151
Study 35614161 — intervention group
Group type: COMPARATOR
Intervention: Observation (no treatment)
Number of subjects: 151
Study 35614161 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronomic chemotherapy (OMC)
Number of subjects: 151
Study 34446053 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course radiotherapy (25 Gray in 5 fractions over one week) with concomitant durvalumab (1500 mg every 4 weeks), followed by FOLFOX (85 mg/m2 oxaliplatin, 350 mg folinic acid, and 400 mg/m2 bolus 5-FU on day 1, followed by 2400 mg/m2 5-FU infusion over 46-48 hours, every 2 weeks) and durvalumab.
Number of subjects: 42
Study 34446053 — intervention group
Group type: COMPARATOR
Intervention: Long course chemoradiotherapy (50 Gray to primary tumour in 25 fractions over 5 weeks with concomitant oral capecitabine 825 mg/m2 twice per day on days of radiotherapy) with durvalumab followed by FOLFOX and durvalumab.
Number of subjects: 42
Study 34446053 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (short course and long course)
Number of subjects: 42
Study 36196729 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (3 mg) + Metformin (2x1,000 mg)
Number of subjects: 276
Study 36196729 — intervention group
Group type: COMPARATOR
Intervention: Metformin monotherapy (2x1,000 mg)
Number of subjects: 276
Study 35639151 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic to mothers, placebo to infants
Number of subjects: 51
Study 35639151 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic to infants, placebo to mothers
Number of subjects: 51
Study 35639151 — intervention group
Group type: COMPARATOR
Intervention: Placebo to both mothers and infants
Number of subjects: 51
Study 32179067 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation‐based cognitive rehabilitation intervention delivered in a group setting during 6 weekly 2.5‐hour classes.
Number of subjects: 61
Study 32179067 — intervention group
Group type: COMPARATOR
Intervention: Wait‐list control group
Number of subjects: 61
Study 36403975 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia iliaca block (FIB) with 30 mL of 0.185% ropivacaine
Number of subjects: 72
Study 36403975 — intervention group
Group type: COMPARATOR
Intervention: Control group (no FIB)
Number of subjects: 72
Study 34952592 — intervention group
Group type: EXPERIMENTAL
Intervention: Community initiated Kangaroo Mother Care (ciKMC)
Number of subjects: 8402
Study 34952592 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 8402
Study 32556602 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib (300 mg) in fed state (high-fat, high-calorie meal)
Number of subjects: 31
Study 32556602 — intervention group
Group type: COMPARATOR
Intervention: Adavosertib (300 mg) in fasted state
Number of subjects: 31
Study 34446531 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTNK‐tPA 0.25 mg/kg (single bolus) to a maximum of 25 mg
Number of subjects: 0
Study 34446531 — intervention group
Group type: COMPARATOR
Intervention: rt‐PA 0.9 mg/kg (10% bolus + 90% infusion/1 hour) to a maximum of 90 mg
Number of subjects: 0
Study 34051780 — intervention group
Group type: EXPERIMENTAL
Intervention: BMR + BET
Number of subjects: 351
Study 34051780 — intervention group
Group type: COMPARATOR
Intervention: BMR + SET
Number of subjects: 351
Study 32155622 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral carbohydrate (POC)
Number of subjects: 63
Study 32155622 — intervention group
Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 63
Study 32155622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 32155622 — intervention group
Group type: COMPARATOR
Intervention: Fasting and Placebo
Number of subjects: 63
Study 36131360 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of SHR4640 and febuxostat
Number of subjects: 0
Study 35021029 — intervention group
Group type: EXPERIMENTAL
Intervention: PIP joint arthrodesis
Number of subjects: 37
Study 35021029 — intervention group
Group type: COMPARATOR
Intervention: PIP joint resection arthroplasty
Number of subjects: 37
Study 32513359 — intervention group
Group type: COMPARATOR
Intervention: Ointment containing Polymyxin B and Bacitracin (Group A, n=28)
Number of subjects: 62
Study 32513359 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnion (Group B, n=34)
Number of subjects: 62
Study 35762293 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (333 mg)
Number of subjects: 18
Study 35762293 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (300 mg)
Number of subjects: 18
Study 35762293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 34455287 — intervention group
Group type: EXPERIMENTAL
Intervention: E_MOTIVA theory‐based adaptive e‐learning program
Number of subjects: 102
Study 34455287 — intervention group
Group type: COMPARATOR
Intervention: E_MOTIVB knowledge‐based standardized e‐learning program
Number of subjects: 102
Study 616738568 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting health care intervention
Number of subjects: 0
Study 35782062 — intervention group
Group type: EXPERIMENTAL
Intervention: miR‐339‐5p mimic
Number of subjects: 0
Study 35782062 — intervention group
Group type: EXPERIMENTAL
Intervention: miR‐339‐5p suppressor
Number of subjects: 0
Study 35782062 — intervention group
Group type: COMPARATOR
Intervention: miR‐NC
Number of subjects: 0
Study 35868849 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully digital pathway for BRCA-testing
Number of subjects: 130
Study 35868849 — intervention group
Group type: COMPARATOR
Intervention: Partially digital pathway via telephone consultation
Number of subjects: 130
Study 32914857 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID‐19 rapid lateral flow immunoassays for seroprevalence testing
Number of subjects: 1234
Study 34823025 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal Web‐based prevention (Climate Schools)
Number of subjects: 2190
Study 34823025 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective prevention for high‐risk students (Preventure)
Number of subjects: 2190
Study 34823025 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined universal and selective prevention (Climate Schools and Preventure [CAP])
Number of subjects: 2190
Study 34823025 — intervention group
Group type: COMPARATOR
Intervention: Health education as usual (control)
Number of subjects: 2190
Study 34496743 — intervention group
Group type: EXPERIMENTAL
Intervention: Monochromatic blue light (MBL) during the first 30 minutes of recovery
Number of subjects: 104
Study 34496743 — intervention group
Group type: COMPARATOR
Intervention: Sham blue light during the first 30 minutes of recovery
Number of subjects: 104
Study 32518098 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 119
Study 32518098 — intervention group
Group type: COMPARATOR
Intervention: Lomustine
Number of subjects: 119
Study 35258113 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist supportive clinical management (SSCM)
Number of subjects: 178
Study 32260470 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 90
Study 32260470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 90
Study 32260470 — intervention group
Group type: COMPARATOR
Intervention: Intensive medical therapy
Number of subjects: 90
Study 32260470 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 36169807 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P16
Number of subjects: 689
Study 36169807 — intervention group
Group type: COMPARATOR
Intervention: EU-bevacizumab
Number of subjects: 689
Study 33545096 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once per day by mouth or intravenously for 10 days or until discharge
Number of subjects: 7763
Study 33545096 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 7763
Study 33545096 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 7763
Study 33545096 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin among those not on invasive mechanical ventilation at baseline
Number of subjects: 7763
Study 32702879 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 146